Q63767 AF NFT

Breast cancer anti-estrogen resistance protein 1

MOLNFT AF v1 smart contract in GenesisL1 blockchain: 
0xBf7491af3407816DFa88a5EA4c82e8A2B1D721eD
IPFS of NFT metadata: 
bafybeigckllje5e6262wu26uxnhoahlhi57w2lhsuwma37oqnlprpagbhi/metadata.json
IPFS of structure file: 
bafybeicjly4mc5oz7tmusv6umja376mu46h4mvnohfprmxnbjxdur3baee/AF-Q63767-F1-model_v2.pdb
First NFT owner address (eip-55): 
0x061709E5c590470B2a4D9a39A6B73b43637aa6A5
First NFT owner address (bech32): 
genesis1qctsnew9jprsk2jdngu6ddemgd3h4f49x6jrnq
Current NFT ID #41207 owner (web3):

First owner GALLERY | EVM EXPLORER | COSMOS EXPLORER

MOLNFT AF v1

NFT id:
41207
Accession (UniProt):
Q63767
Name::
Breast cancer anti-estrogen resistance protein 1
Experimental Method:
Predicted structure
Sequence source:
RATTUS NORVEGICUS

NFT data

MolNFT AF v1 is an AlphaFold database of AI predicted Swiss-Prot protein sequences preserved as regular ERC-721 NFT tokens on GenesisL1 blockchain for public free use, research and entertainment:

https://alphafold.ebi.ac.uk/
Jumper, J., Evans, R., Pritzel, A. et al. Highly accurate protein structure prediction with AlphaFold. 
Nature 596, 583–589 (2021). https://doi.org/10.1038/s41586-021-03819-2

MOLNFT Q63767 research and analysis (ICN3D with VR)

FASTA sequences

>sp|Q63767|BCAR1_RAT Breast cancer anti-estrogen resistance protein 1 OS=Rattus norvegicus OX=10116 GN=Bcar1 PE=1 SV=1 MKYLVSVGAGPARRAGGLEDVSWGPRVSRRPQSYRAARHVNESLPRSAFRVPAAHGASVTPSAALGSGLPETQPEAVCRGTEKPRFAEGCKPAASRDKNVLAKALYDNVAESPDELSFRKGDIMTVLERDTQGLDGWWLCSLHGRQGIVPGNRLKILVGMYDKKPAAPGPGPPATPPQPQPSLPQGVHTPVPPASQYSPMLPTAYQPQPDNVYLVPTPSKTQQGLYQAPGPNPQFQSPPAKQTSTFSKQTPHHSFPSPATDLYQVPPGPGSPAQDIYQVPPSAGTGHDIYQVPPSLDTRSWEGTKPPAKVVVPTRVGQGYVYEASQAEQDEYDTPRHLLAPGSQDIYDVPPVRGLLPNQYGQEVYDTPPMAVKGPNGRDPLLDVYDVPPSVEKGLPPSNHHSVYDVPPSVSKDVPDGPLLREETYDVPPAFAKPKPFDPTRHPLILAAPPPDSPPAEDVYDVPPPAPDLYDVPPGLRRPGPGTLYDVPRERVLPPEVADGSVIDDGVYAVPPPAEREAPTDGKRLSASSTGSTRSSQSASSLEVVVPGREPLELEVAVETLARLQQGVSTTVAHLLDLVGSASGPGGWRSTSEPQEPPVQDLKAAVAAVHGAVHELLEFARSAVSSATHTSDRTLHAKLSRQLQKMEDVYQTLVVHGQVLDSGRGGPGFTLDDLDRLVACSRAVPEDAKQLASFLHGNASLLFRRTKAPGPGPEGSSSLHLNPTDKASSIQSRPLPSPPKFTSQDSPDGQYENSEGGWMEDYDYVHLQGKEEFEKTQKELLEKGNIVRQGKGQLELQQLKQFERLEQEVSRPIDHDLANWTPAQPLVPGRTGGLGPSDRQLLLFYLEQCEANLTTLTDAVDAFFTAVATNQPPKIFVAHSKFVILSAHKLVFIGDTLSRQAKAADVRSKVTHYSNLLCDLLRGIVATTKAAALQYPSPSAAQDMVDRVKELGHSTQQFRRVLGQLAAA